Entity

Time filter

Source Type


Stoetzer O.J.,Haematology and Oncology Outpatient Cancer Care Center | Fersching D.M.I.,Ludwig Maximilians University of Munich | Salat C.,Haematology and Oncology Outpatient Cancer Care Center | Steinkohl O.,Breast Cancer Center Klinikum Dritter Orden | And 9 more authors.
Tumor Biology | Year: 2013

Neoadjuvant chemotherapy in breast cancer patients aims at preoperative reduction of tumor volume for better resection results and prognosis. As not all patients respond to neoadjuvant therapy, predictive biomarkers are needed for more efficient individual management. In prospectively collected sera of 51 consecutive locally confined breast cancer (LBC) patients receiving preoperative, neoadjuvant chemotherapy, value level kinetics of soluble high mobility group box 1 (HMGB1), soluble receptor for advanced glycation end products (sRAGE) as well as the established breast cancer biomarkers CA 15-3 and carcinoembryonic antigen (CEA) were investigated and correlated with therapy response objectified by pathological staging at surgery. In addition, biomarkers were measured in sera of 30 healthy controls (HC), 13 patients with benign breast diseases, and 28 metastatic breast cancer (MBC) patients. Pretherapeutic levels of soluble HMGB1 were decreased in MBC, while sRAGE was already decreased in LBC. In contrast, CA 15-3 and CEA were strongly elevated in MBC, but not in LBC. Combination of sRAGE and CA 15-3 enabled best discrimination of LBC from HC (AUC 78.2 %; sens 58 % at 95 % spec), while CA15-3 and CEA discriminated best between MBC and all controls (AUC 90.9 %; sens 70 % at 95 % spec). In LBC patients undergoing neoadjuvant chemotherapy, nine patients achieved complete remission (CR), 29 achieved partial remission (PR), while 13 had no change of disease (NC). NC patients tended to have higher HMGB1 and lower sRAGE levels before therapy onset (p = 0.056 and p = 0.054), while CA 15-3 and CEA did not predict therapeutic outcome. Furthermore, kinetics of HMGB1 during therapy correlated with efficacy of the treatment (p = 0.053). Markers of immunogenic cell death are valuable for the diagnosis of MBC and early estimation of response to neoadjuvant therapy in LBC patients. © 2012 International Society of Oncology and BioMarkers (ISOBM). Source


Stoetzer O.J.,Haematology and Oncology Outpatient Cancer Care Center | Fersching D.M.I.,Ludwig Maximilians University of Munich | Salat C.,Haematology and Oncology Outpatient Cancer Care Center | Steinkohl O.,Breast Cancer Center Klinikum Dritter Orden | And 9 more authors.
Cancer Letters | Year: 2013

Biomarkers predicting response to neoadjuvant chemotherapy in locally confined breast cancer (LBC) are highly needed. We prospectively assessed serial blood levels of apoptotic biomarkers nucleosomes, DNAse activity, cytokeratin-18 fragments (M30) and survivin in 51 LBC patients and correlated them with response to neoadjuvant treatment and established tumor markers. As controls, we used 31 healthy subjects, 13 patients with benign diseases and 28 with metastatic breast cancer (MBC). Levels of nucleosomes and survivin were elevated in LBC and MBC while M30, CEA and CA 15-3 levels were only elevated in MBC. During neoadjuvant chemotherapy, LBC patients with no change of disease (N = 13) had significantly higher pretherapeutic levels of nucleosomes than patients with remission (N = 38). We conclude that apoptotic biomarkers bear valuable information for diagnosis and therapy response prediction in LBC patients. © 2013 Elsevier Ireland Ltd. Source

Discover hidden collaborations